Acquiring Company
GSK plc
Acquired Company
ChImagen Biosciences
Philadelphia
BeratManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
GSK plc has announced its agreement to acquire a trispecific T-cell engager from ChImagen Biosciences. The agreement includes full global rights to the program, with a total potential value of up to $750 million. GSK plans to develop and commercialize the asset for treatment in multiple myeloma, targeting Phase I trials in 2027.
Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ChImagen Biosciences?
ChImagen Biosciences was acquired by GSK plc, based in Philadelphia. The deal was reported on October 3, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.
When did GSK plc acquire ChImagen Biosciences?
GSK plc's acquisition of ChImagen Biosciences was reported on October 3, 2026. GSK plc has announced its agreement to acquire a trispecific T-cell engager from ChImagen Biosciences. The agreement includes full global rights to the program, with a total potential value of up to $750 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ChImagen Biosciences do?
ChImagen Biosciences specializes in developing novel therapeutics for various diseases, including multiple myeloma. Their innovative approaches focus on using advanced biotherapeutic platforms. It is privately held, operating in Biotechnology, and is based in Berat.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.